Stoke Therapeutics
Stoke Therapeutics appoints Thomas McCauley as Chief Scientific Officer
McCauley most recently served as the President and CEO of Neptune Bio
Biogen gains rights to Stoke’s Dravet syndrome candidate in deal worth $550m
The rare genetic epilepsy affects up to 38,000 people in the US, UK, EU and Japan
‘Missing protein’ biotech Stoke raises $142m in IPO
Continues pioneering research